US 12,239,982 B2
Microfluidic device and diagnostic methods for allergy testing based on detection of basophil activation
Sindy K. Y. Tang, Palo Alto, CA (US); Kari C. Nadeau, Los Altos Hills, CA (US); Bryan J. Bunning, San Mateo, CA (US); Nicolas Castano, Stanford, CA (US); Fengjiao Lyu, Stanford, CA (US); and Seth Cordts, Palo Alto, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 17/292,782
Filed by Sindy K. Y. Tang, Palo Alto, CA (US); Kari C. Nadeau, Los Altos Hills, CA (US); Bryan J. Bunning, San Mateo, CA (US); Nicolas Castano, Stanford, CA (US); Fengjiao Lyu, Stanford, CA (US); Seth Cordts, Palo Alto, CA (US); and The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Nov. 13, 2019, PCT No. PCT/US2019/061288
§ 371(c)(1), (2) Date May 11, 2021,
PCT Pub. No. WO2020/102429, PCT Pub. Date May 22, 2020.
Claims priority of provisional application 62/888,884, filed on Aug. 19, 2019.
Claims priority of provisional application 62/767,444, filed on Nov. 14, 2018.
Prior Publication US 2021/0394183 A1, Dec. 23, 2021
Int. Cl. B01L 1/00 (2006.01); B01L 3/00 (2006.01); G01N 33/50 (2006.01); G01N 33/543 (2006.01); G01N 33/569 (2006.01)
CPC B01L 3/502761 (2013.01) [G01N 33/5047 (2013.01); G01N 33/54366 (2013.01); G01N 33/56972 (2013.01); B01L 2200/0652 (2013.01); B01L 2300/0819 (2013.01); B01L 2300/088 (2013.01); B01L 2300/0883 (2013.01); G01N 2800/24 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A microfluidic chip component comprising:
a) an allergen test chamber comprising an allergen;
b) a first region for separating basophils from other blood cells by negative selection, wherein the first region comprises a plurality of immobilized binding agents capable of selectively binding to one or more cell surface markers on the other blood cells, wherein the cell surface markers are not expressed on basophils;
c) a first fluidic channel, wherein the first fluidic channel connects the chamber comprising an allergen to the first region;
d) a second region for capturing basophils by positive selection, wherein the second region comprises a plurality of immobilized binding agents capable of selectively binding to one or more cell surface markers on the basophils and capturing the basophils;
e) a second fluidic channel, wherein the second fluidic channel connects the first region to the second region; and
f) a means for detecting basophils activated by the allergen.